Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) had its price objective trimmed by Stifel Nicolaus from $55.00 to $46.00 in a report issued on Wednesday, The Fly reports.
ZNTL has been the topic of a number of other reports. UBS Group decreased their price objective on Zentalis Pharmaceuticals to $52.00 in a research note on Monday, November 21st. HC Wainwright reiterated a buy rating and set a $55.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 2nd. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of Buy and a consensus target price of $43.44.
Zentalis Pharmaceuticals Trading Down 0.5 %
ZNTL stock opened at $18.83 on Wednesday. The stock’s fifty day simple moving average is $20.81 and its two-hundred day simple moving average is $21.73. Zentalis Pharmaceuticals has a 1-year low of $15.55 and a 1-year high of $52.85. The stock has a market cap of $1.12 billion, a P/E ratio of -4.16 and a beta of 1.87.
Insider Transactions at Zentalis Pharmaceuticals
In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 10,000 shares of the stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $21.02, for a total transaction of $210,200.00. Following the sale, the president now directly owns 362,011 shares of the company’s stock, valued at approximately $7,609,471.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, President Cam Gallagher sold 10,000 shares of the firm’s stock in a transaction dated Thursday, January 5th. The shares were sold at an average price of $21.02, for a total value of $210,200.00. Following the transaction, the president now directly owns 362,011 shares of the company’s stock, valued at approximately $7,609,471.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Melissa B. Epperly sold 2,624 shares of the firm’s stock in a transaction that occurred on Monday, February 13th. The stock was sold at an average price of $20.42, for a total transaction of $53,582.08. Following the sale, the chief financial officer now owns 397,275 shares of the company’s stock, valued at approximately $8,112,355.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,763 shares of company stock valued at $873,760. Corporate insiders own 19.90% of the company’s stock.
Institutional Investors Weigh In On Zentalis Pharmaceuticals
Several institutional investors have recently modified their holdings of ZNTL. Captrust Financial Advisors lifted its position in Zentalis Pharmaceuticals by 15,160.0% in the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after acquiring an additional 758 shares during the last quarter. US Bancorp DE increased its stake in shares of Zentalis Pharmaceuticals by 378.9% during the first quarter. US Bancorp DE now owns 1,451 shares of the company’s stock worth $67,000 after acquiring an additional 1,148 shares during the period. Point72 Hong Kong Ltd acquired a new position in shares of Zentalis Pharmaceuticals during the first quarter worth about $72,000. Great West Life Assurance Co. Can acquired a new position in shares of Zentalis Pharmaceuticals during the third quarter worth about $48,000. Finally, Metropolitan Life Insurance Co NY grew its position in Zentalis Pharmaceuticals by 24.1% during the third quarter. Metropolitan Life Insurance Co NY now owns 2,828 shares of the company’s stock worth $61,000 after buying an additional 550 shares during the period.
Zentalis Pharmaceuticals Company Profile
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.